EcoDrugPlus

Serine (Or Cysteine) Peptidase Inhibitor, Clade C (Antithrombin), Member 1

Ensembl ID : ENSMAUG00000019496
Gene Symbol: SERPINC1
1 Cross references
199 Possible Orthologues:

Serine/threonine-Protein Kinase Pim-1

Ensembl ID : ENSMAUG00000000565
Gene Symbol: LOC101836687
3 Cross references
243 Possible Orthologues:

Serine/threonine-Protein Kinase Pim-1

Ensembl ID : ENSMAUG00000010003
Gene Symbol: LOC101836961
3 Cross references
243 Possible Orthologues:

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSMAUG00000011503
Gene Symbol: SIGMAR1
4 Cross references
204 Possible Orthologues:

Sirtuin 1

Ensembl ID : ENSMAUG00000008395
Gene Symbol: SIRT1
1 Cross references
155 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSMAUG00000010178
Gene Symbol: SMO
1 Cross references
204 Possible Orthologues:

Sodium Channel Epithelial 1 Subunit Gamma

Ensembl ID : ENSMAUG00000014359
Gene Symbol: SCNN1G
4 Cross references
155 Possible Orthologues:

Sodium Channel, Nonvoltage-Gated 1 Beta

Ensembl ID : ENSMAUG00000013262
Gene Symbol: SCNN1B
1 Cross references
151 Possible Orthologues:

Sodium Channel, Voltage-Gated, Type Ii, Alpha

Ensembl ID : ENSMAUG00000004805
Gene Symbol: SCN2A
1 Cross references
130 Possible Orthologues:

Sodium Channel, Voltage-Gated, Type Ix, Alpha

Ensembl ID : ENSMAUG00000007261
Gene Symbol: SCN9A
1 Cross references
110 Possible Orthologues:

Sodium Channel, Voltage-Gated, Type X, Alpha

Ensembl ID : ENSMAUG00000014414
Gene Symbol: SCN10A
1 Cross references
297 Possible Orthologues:

Sodium Channel, Voltage-Gated, Type Xi, Alpha

Ensembl ID : ENSMAUG00000007489
Gene Symbol: SCN11A
1 Cross references
96 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).